Resolution of inflammation is altered in Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 1, 2015, Pages 40-50.e2

  Wang, Xiuzhe ^a   Zhu, Mingqin ^a   Hjorth, Erik ^a   Cortés Toro, Veronica ^a   Eyjolfsdottir, Helga ^a   Graff, Caroline ^a   Nennesmo, Inger ^a   Palmblad, Jan ^a   Eriksdotter, Maria ^a   Sambamurti, Kumar ^b   Fitzgerald, Jonathan M ^c   Serhan, Charles N ^c   Granholm, Ann Charlotte ^b   Schultzberg, Marianne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

15 Lipoxygenase 2; ALX FPR2; ChemR23; ELISA; FPRL1; Human; Immunohistochemistry; Lipoxin A4; Mild cognitive impairment; Resolvin D1; Specialized pro resolving mediators; Tau

Indexed keywords

ENZYME; LIPOXIN A; RECEPTOR; SPECIALIZED PRO RESOLVING MEDIATOR; SPECIALIZED PRO RESOLVING MEDIATOR RECEPTOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AUTACOID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; FORMYLPEPTIDE RECEPTOR; FPR2 PROTEIN, HUMAN; LIPOXIN; LIPOXIN RECEPTOR; LIPOXYGENASE; RESOLVIN D1; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; CASE CONTROL STUDY; ENZYMOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CASE-CONTROL STUDIES; DOCOSAHEXAENOIC ACIDS; FEMALE; HIPPOCAMPUS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; LIPOXYGENASE; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; TAU PROTEINS;

EID: 84922772032     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.024     Document Type: Article

References (50)

1. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010;56:484-546.
2. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers RD, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001;358:461-7.
3. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989;86:7611-5.
4. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68:930-41.
5. Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer's disease. J Neuropathol Exp Neurol 1993;52:601-8.
6. Combs CK, Karlo JC, Kao SC, Landreth GE. b-Amyloid stimulation of microglia and monocytes results in TNFa-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001;21:1179-88.
7. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28:639-47.
8. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010;177:1576-91.
9. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325-32.
10. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984;81:5335-9.
11. Serhan CN. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1994;1212:1-25.
12. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 1996;183:137-46.
13. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for antiinflammatory receptors. J Exp Med 1997;185:1693-704.
14. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010;1801:1260-73.
15. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994;180:253-60.
16. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 2010;24:4240-9.
17. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 2012;180:2018-27.
18. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010;107:1660-5.
19. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005;201:713-22.
20. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 2011;11:629-47.
21. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005;115:2774-83.
22. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo JM, et al. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPAR-g-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 2009;29:3875-84.
23. Wu Y, Zhai H, Wang Y, Li L, Wu J, Wang F, et al. Aspirin-triggered lipoxin A (4) attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase. Neurochem Res 2012;37:1690-6.
24. Decker Y, McBean G, Godson C. Lipoxin A4 inhibits IL-1b-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol 2009;296:C1420-7.
25. Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs DH, et al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol 2013;182:1780-9.
26. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010;16:592-7.
27. ICD-10: International statistical classification of diseases and related health problems 10th ed. Geneva: World Health Organization; 2009.
28. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
30. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012;120:e60-72.
31. Sarlus H, Höglund CO, Karshikoff B, Wang X, Lekander M, Schultzberg M, et al. Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation. J Cell Mol Med 2012;16:2401-12.
32. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-9.
33. Thal DR, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D, et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 2000;163:98-110.
34. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van De Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol 1992;84:265-72.
35. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR-g-mediated mechanisms in Alzheimer's disease models. PLoS One 2011;6:e15816.
36. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A 1997;94:6148-52.
37. Waechter V, Schmid M, Herova M, Weber A, Gunther V, Marti-Jaun J, et al. Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages. J Immunol 2012;188:1856-67.
38. Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, et al. Amyloid b42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 2001;21: RC123.
39. Kitamura Y, Shimohama S, Koike H, Kakimura J-I, Matsuoka Y, Nomura Y, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-g in Alzheimer's disease brains. Biochem Biophys Res Commun 1999;254:582-6.
40. Remarque EJ, Bollen EL, Weverling-Rijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp Gerontol 2001;36:171-6.
41. Bagnoli S, Cellini E, Tedde A, Nacmias B, Piacentini S, Bessi V, et al. Association of IL10 promoter polymorphism in Italian Alzheimer's disease. Neurosci Lett 2007;418:262-5.
42. Souza DG, Fagundes CT, Amaral FA, Cisalpino D, Sousa LP, Vieira AT, et al. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007;179:8533-43.
43. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998;251:189-92.
44. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 2008;56:1065-73.
45. Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, et al. 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 2004;164:1655-62.
46. Higgs GA, Bax CM, Moncada S. Inflammatory properties of lipoxygenase products and the effects of indomethacin and BW755C on prostaglandin production, leukocytemigration, and plasma exudation in rabbit skin. Adv Prostaglandin Thromboxane Leukot Res 1982;9:331-9.
47. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2:612-9.
48. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-85.
49. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
50. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999;7:254-66.